$SMED $RVP selling the EasyPoint® needle in 2016. Sales in 2017 and 2018 for this product were 6.0% and 10.3%, respectively, of our total revenues. Based on industry-wide trends, we anticipate that demand increase for the EasyPoint® needle. Following the expiration of such patent, competitors will be permitted to attempt to copy the VanishPoint® syringe as presently manufactured. Patents cover future modifications to the VanishPoint® syringe and core technology of the VanishPoint® syringe will expire during the years 2028 through 2032. If the VanishPoint® syringes are changed to incorporate the modifications covered in the unexpired patents, then competitors won’t be permitted to attempt to copy such modified syringes in the countries where the patents remain in effect.